enGene Therapeutics ENGN
NASDAQ ENGN
$1.58 -0.05 (-3.07%)
At close: Oct 22, 2026 · 4:00 PM EDT

enGene Therapeutics (ENGN) Convertible Debt (2022)

Updated

enGene Therapeutics' Convertible Debt was $17.41 million in fiscal Q4 2022 (quarter ended Oct 31, 2022).

Analysis

enGene Therapeutics (ENGN) Convertible Debt (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn
10 enGene Therapeutics 105.88 Mn -888.59 Mn -
Historic Data

Historic Data

Download Data
DateValue
Oct 31, 2022 17.41 Mn
API Access

enGene Therapeutics Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=ENGN&period=max&api_key=YOUR_API_KEY